ELSEVIER

DRUG DISCOVERY TODAY

June 2019
Volume 24 Number 7
pp. 1321–1424



Cover Story
The lead story in this issue of *Drug Discovery Today* is by A. Prasanth Saraswati, Nicola Relitti, Margherita Brindisi, Sandra Gemma, Daniela Zisterer, Stefania Butini and Giuseppe Campiani of the University of Siena, Italy. They review recent advances in the development of telomerase inhibitors as anticancer agents and highlight the advantages of targeting telomerases in cancer therapy

EDITORIAL

Serendipitous drug repurposing through social media
Daniel P. Kelly and Julie Blatt
1321

PERSPECTIVE

FEATURE

Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review
Vikas Soekhai, Chiara Whichello, Bennett Levitan, Jorien Veldwijk, Cathy Anne Pinto, Bas Donkers, Isabelle Huys, Eline van Overbeeke, Juhaeri Juhaeri and Esther W. de Bekker-Grob
1324

REVIEWS

FOUNDATION

Machine learning on adverse drug reactions for pharmacovigilance
Chun Yen Lee and Yi-Ping Phoebe Chen
1332

Better prediction of the local concentration–effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development
Sebastian Polak, Zofia Tylutki, Mark Holbrook and Barbara Wiśniowska
1344

Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options
Daniel Nisakar Meenakshi Sundaram, Xiaoyan Jiang, Joseph M. Brandwein, Juliana Valencia-Serna, K.C. Remant and Hasan Uludağ
1355

KEYNOTE

Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors
A. Prasanth Saraswati, Nicola Relitti, Margherita Brindisi, Sandra Gemma, Daniela Zisterer, Stefania Butini and Giuseppe Campiani
1370

ScienceDirect